Congress Materials - ASCO Genitourinary Cancers (ASCO GU 2026)
2026 ASCO Genitourinary Cancers | Feb 26-28 | San Francisco, CA
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Clinical Validity of FoundationOne CDx Assay to Identify HRR-Positive or BRCA-Positive mCSPC Patients in the Phase 3 AMPLITUDE Study
Usha Singh, Victoria Zadorozhny, Lesley Farrington, Katherine Bell, Gary V. Borzillo, Fei Shen, Sharon McCarthy, Carly R. Varela, Daneen Schaeffer, Suneel Dinkar Mundle, Yueyi (Kate) Li, Ta-Chou (Vincent) Ng, Songbai Wang
Deep PSA Decline in the Chinese Subgroup of LIBERTAS, a Phase 3 Study of Apalutamide Plus Continuous Versus Intermittent Androgen Deprivation Therapy in Metastatic Castration-Sensitive Prostate Cancer
Qiang Dong, Lei Li, Zhenhua Li, Jiaju Lyu, Chunxi Wang, Wanlong Tan, Shaogang Wang, Junhui Jiang, Alex Dos Santos, Sukie Shopeju, Amitabha Bhaumik, Suneel Dinkar Mundle, Sharon McCarthy, Anildeep Singh, Lijun Zhang, Na Chen, Mark A. Wildgust, Arun Azad, Neeraj Agarwal
Fostering Inclusive Language for Genitourinary Cancer Research: A Multi-Stakeholder Co-Creation Effort
Alex Filicevas, Keith D. Crawford, Jola Ignaciuk, Michelle C. Hull
Front-line treatment and recurrence patterns among patients with high-risk non–muscle-invasive bladder cancer with papillary carcinoma or carcinoma in situ following Bacillus Calmette-Guérin or other intravesical therapies
Michael Fabrizio, Mukul Singhal, Bruno Emond, Carmine Rossi, Rebecca Bungay, Steven Liu, Dominic Pilon, Ali R. Khaki
Gemcitabine Intravesical System (Gem-iDRS) in Combination With Cetrelimab (CET) Versus Chemoradiotherapy (CRT) in Muscle-Invasive Bladder Cancer (MIBC): SunRISe-2 Final Results
Andrea Necchi, Stephen B. Williams, Phuoc Tran, Yohann Loriot, Mariaconsiglia Ferriero, Hernan Cutuli, Makito Miyake, Gunter Niegisch, Paul Nguyen, Siamak Daneshmand, Felipe Villacampa-Aubá, Wolfgang Jessner, Meggan Tammaro, Marietta Kashmer, Jenna Carcione, Monelle Tamegnon, Hussein Sweiti, Robert A. Somer, Sumeet K. Bhanvadia, Shahrokh F. Shariat
Impact of Baseline Hot Flashes on Sleep Metrics During Initial Treatment in LIBERTAS Clinical Trial
Arun Azad, Marco A. Badillo, Alicia K. Morgans, Dana Rathkopf, Karie Runcie, Geoffrey Gotto, Axel S. Merseburger, Alex Dos Santos, Sukie Shopeju, Meenakshi Chatterjee, Rana Zia Ur Rehman, Daniel P. Sanchez, Bhavini Patel, Amitabha Bhaumik, Simon Todd, Yanran Huo, Mark A. Wildgust, Neeraj Agarwal
Neoadjuvant Gemcitabine Intravesical System (Gem-iDRS) Plus Cetrelimab or Cetrelimab Alone in Patients With Muscle-Invasive Bladder Cancer Ineligible for/Refusing Neoadjuvant Cisplatin-Based Chemotherapy: Updated Perioperative Outcomes From SunRISe-4
Sarah P. Psutka, Bernardo Herrera Imbroda, Paul Crispen, Andrea Necchi, Rohan Garje, Bernadett E. Szabados, Charles Peyton, Benjamin Pradere, Neal D. Shore, Martin Boegemann, Mark Preston, Evanguelos Xylinas, Cinty Gong, Mohamad Hasan, Hind Stitou, Sumeet K. Bhanvadia, Won Kim, Félix Guerrero-Ramos
Patterns of Management and Multidisciplinary Care in High/Very High and Intermediate Risk Prostate Cancer: A Population-Based Study in Ontario, Canada
Christopher J. Wallis, Shawn Malone, Ilias Cagiannos, Robert J. Hamilton, Naveen S. Basappa, Cristiano Ferrario, Geoffrey Gotto, Ricardo Fernandes, Tamim Niazi, Christopher Morash, Ricardo Rendon, Fred Saad, Sebastien J. Hotte, Brendan Osborne, Anousheh Zardan, Bobby Shayegan
Phase 1 Safety, Efficacy, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Pasritamig in Asian Population With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Junyong Dai, Nan Liu, Yonghong Li, Zhixian Yu, Shudong Zhang, Takashi Kawahara, Hiroji Uemura, Chihiro Kondo, Daria Gaut, Regina J. Brown, Leanne Cartee, Yanmei Liu, Junya Aoyama, Haocheng Ma, Ei Fujikawa, Debopriya Ghosh, Kristin M. Shotts, Ruchi Chaudhary, Siew Kee Low, Nobuaki Matsubara
Quality of care measures among patients with recurrent, papillary-only bacillus Calmette-Guérin experienced high-risk nonmuscle invasive bladder cancer
Ali R. Khaki, Mukul Singhal, Bruno Emond, Carmine Rossi, Rebecca Bungay, Steven Liu, Dominic Pilon, Michael Fabrizio
Real-World Clinical Outcomes Among Patients With Localized Prostate Cancer Undergoing Radical Prostatectomy
Neal D. Shore, Benjamin H. Lowentritt, Charmi Patel, Frederic Kinkead, Sabree Burbage, Carmine Rossi, Yuxi Wang, Gordon Wong, Francesca Lee, Dominic Pilon, Lawrence I. Karsh, Gordon A. Brown
Real-World Comparison of Prostate-Specific Antigen Response in Metastatic Castration-Sensitive Prostate Cancer Patients Treated With Apalutamide Without Docetaxel vs Darolutamide Without Docetaxel
Mehmet A. Bilen, Gordon A. Brown, Mukul Singhal, Carmine Rossi, Frederic Kinkead, Gordon Wong, Alessio Palladino, Dominic Pilon, Courtney Morrow, Benjamin D. Lowentritt
Safety and Efficacy of Pasritamig (PAS) + Docetaxel (DOCE) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC): Initial Results of a Phase 1b Study
Manish R. Patel, Russell K. Pachynski, Shahneen Sandhu, Aaron R. Hansen, Kevin K. Zarrabi, Craig Gedye, Nehal J. Lakhani, Howard Gurney, Justin M. Lebenthal, Mary K. O’Keeffe, Samantha Hopkins, Nancy Huang, Debopriya Ghosh, Ligi Mathews, Regina J. Brown, Vincent Lin, Josh D. Lauring, Sherry C. Wang, Victor M. Villalobos, David R. Wise
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.